ArticleFrontiers in public health2022

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.

Zhiwei Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.